Scleroderma Newsroom
ISN News Manager: Jo Frowde
Media Stories
Autoimmune Archive
2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2018 - 2017 - 2016 - 2015

June 2016 Autoimmune News

Differences in disease phenotype and severity in systemic lupus erythematosus (SLE) across age groups. Direct comparison of juvenile–onset SLE (JSLE) with adult–onset SLE suggest an aggressive phenotype of disease with a worse outcome in patients with JSLE and emphasizes the importance of careful follow–up in this population. PubMed, Lupus, 05/04/2016. (Also see Pediatric Lupus)

Intrarenal macrophage infiltration induced by T cells is associated with podocyte injury in lupus nephritis patients. The present study provides possible links between intrarenal T cells, osteopontin, macrophages with reduced podocyte–nephrin and podocytopathy in systemic lupus erythematosus. PubMed, Lupus, 05/04/2016. (Also see Symptoms and Complications of Lupus and B Cells and T Cells)

Comparison of heart rate variability (HRV) and classic autonomic testing for detection of cardiac autonomic dysfunction (CAD) in patients with fibromyalgia. HRV does not improve detection of CAD in FM patients over classic autonomic testing. PubMed, Int J Rheum Dis, 04/29/2016. (Also see Fibromyalgia)

Impaired lung transfer factor (DLCO) in fibromyalgia (FM) syndrome. FM impairs DLCO mainly as a result of a reduction in vital capacity (Vc), and that this defect is inversely proportional to the severity of the dysfunction suggesting a relationship between impaired DLCO and autonomic nerve dysfunction. Clinical and Experimental Rheumatology Online, 05/06/2016. (Also see Fibromyalgia)

The impact of fibromyalgia (FM) on health status according to the types, demographic background and pain index. Widespread pain index (WPI) is probably is the most important single indicator of disease severity and quality of life in FM and Type B constitutes a minor but important component of FM. Clinical and Experimental Rheumatology Online, 05/05/2016. (Also see Fibromyalgia)

Cardiovascular (CV) risk in rheumatoid arthritis (RA): assessment, management and next steps. Tight control of disease activity, management of traditional risk factors and lifestyle modification represent, amongst others, the most important steps in improving CV disease outcomes in RA patients. Sage Journals, Therapeutic Advances in Musculoskeletal Disease, 05/10/2016. (Also see Symptoms and Complications of Rheumatoid Arthritis)

Psoriatic arthritis (PsA) and psoriasis: differential diagnosis. The aim of this review is to focus on PsA and psoriasis differential diagnosis. Springer Link, 05/07/2016. (Also see Psoriasis and Psoriatic Arthritis)

Clinical profile and outcome of patients with rheumatoid arthritis (RA) and abnormally high aortic stiffness (AoSI). Increased AoSI is common, can be predicted by an ordinary clinical assessment and is a strong predictor of adverse clinical outcome at mid–term follow–up in patients with RA. Sage Journals, European Journal of Preventive Cardiology, 05/10/2016. (Also see Symptoms and Complications of Rheumatoid Arthritis)

The role of mineral and bone disorders (MBD) in the development and progression of cardiac and renal pathology in patients with type 1 diabetes mellitus of long duration. Development and progression of kidney dysfunction is accompanied by MBD, a significant factor in progression of cardiac pathology, which remains a major cause of mortality in this patient population. Diabetes Research and Clinical Practice, 05/03/2016. (Also see Symptoms and Complications of Diabetes)

Anti–Sm is associated with the early poor outcome of lupus nephritis. Our data suggest that anti–Sm identified at kidney biopsy might have a predictive value for the early poor outcome of biopsy–proven lupus nephritis during the follow–up period. PubMed, Int J Rheum Dis, 04/29/2016. (Also see Symptoms and Complications of Lupus and Antibodies in Lupus)

Go to Autoimmune News: May 2016

Giving Assistant
United Way of Central New Mexico
United Way of Snohomish County
See ISN News for recent donors, including Pam Hop, Margaret Roof, Winifred Schillberg, Arnold Slotkin, and Juliet Youkhana. Plus donations in honor of Kim Thwaits, and in loving memory of Marta Marx, Jim Miller, and Arlene Marie Petulla.
Click Here to Donate or Shop
or click on the floating green DONATE button.


TOLL FREE HOTLINE, U.S. and Canada: 1-800-564-7099
Ask for our Free Info Packet by email or postal mail!

SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, or to report bad links or to update this page content. Privacy Policy.

The most important thing in the world to know about scleroderma is!

Donate Now
Copyright 1998-2018, International Scleroderma Network. AKA Scleroderma from A to Z and SCLERO.ORG. All Rights Reserved.